TANDEM Peptide Receptor Radionuclide Therapy Using [225Ac]Ac-/[177Lu]Lu-DOTA-LM3 in a Patient With Parotid Gland Metastasis From Pancreatic Neuroendocrine Neoplasm.
Elisabetta Perrone, Kriti Ghai, Aleksandr Eismant, Richard P Baum
{"title":"TANDEM Peptide Receptor Radionuclide Therapy Using [225Ac]Ac-/[177Lu]Lu-DOTA-LM3 in a Patient With Parotid Gland Metastasis From Pancreatic Neuroendocrine Neoplasm.","authors":"Elisabetta Perrone, Kriti Ghai, Aleksandr Eismant, Richard P Baum","doi":"10.1097/RLU.0000000000005782","DOIUrl":null,"url":null,"abstract":"<p><p>We present the case of a young 38-year-old woman with metastatic progressive pancreatic neuroendocrine neoplasm (NEN) exhibiting an unusual metastasis to the parotid gland. After previous treatments, including radionuclide therapy with the somatostatin-receptor agonist DOTATOC and parotid metastasectomy, failed, she was referred to TANDEM peptide receptor radionuclide therapy (PRRT) using the somatostatin-receptor antagonist DOTA-LM3 labeled with Actinium-225 and Lutetium-177. Following 2 cycles of TANDEM-PRRT, she achieved partial remission in all metastatic sites, notably in the parotid gland and liver. This is the first reported case of metastatic pancreatic NEN with parotid involvement treated with TANDEM-PRRT.</p>","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":9.6000,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Nuclear Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/RLU.0000000000005782","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
Abstract
We present the case of a young 38-year-old woman with metastatic progressive pancreatic neuroendocrine neoplasm (NEN) exhibiting an unusual metastasis to the parotid gland. After previous treatments, including radionuclide therapy with the somatostatin-receptor agonist DOTATOC and parotid metastasectomy, failed, she was referred to TANDEM peptide receptor radionuclide therapy (PRRT) using the somatostatin-receptor antagonist DOTA-LM3 labeled with Actinium-225 and Lutetium-177. Following 2 cycles of TANDEM-PRRT, she achieved partial remission in all metastatic sites, notably in the parotid gland and liver. This is the first reported case of metastatic pancreatic NEN with parotid involvement treated with TANDEM-PRRT.
期刊介绍：
Clinical Nuclear Medicine is a comprehensive and current resource for professionals in the field of nuclear medicine. It caters to both generalists and specialists, offering valuable insights on how to effectively apply nuclear medicine techniques in various clinical scenarios. With a focus on timely dissemination of information, this journal covers the latest developments that impact all aspects of the specialty.
Geared towards practitioners, Clinical Nuclear Medicine is the ultimate practice-oriented publication in the field of nuclear imaging. Its informative articles are complemented by numerous illustrations that demonstrate how physicians can seamlessly integrate the knowledge gained into their everyday practice.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
